RxDoctor Payments Data

Amy Kemmerlin, NP

Women's Health · Charlotte, NCNPI 1891389656

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.8% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,595 and has fallen 50.7% since, to $1,280 in 2025. Among women's health clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,202in general payments, 2019–2025

Across 319 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$756
  • Johnson & Johnson$489
  • Novartis$477
  • Astellas Pharma US Inc$458
  • Pfizer$362
  • Merck$309
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,44591%
  • Education$7579%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)25$756
Johnson & Johnson(2 entities)17$489
Novartis20$477
Astellas Pharma US Inc12$458
Pfizer18$362
Merck14$309
Eisai Inc.12$268
Incyte Corporation9$261
Takeda Pharmaceuticals U.S.A., Inc.9$244
Stemline Therapeutics Inc.6$219
E.r. Squibb & Sons, L.L.C.9$213
AVEO Pharmaceuticals, Inc.6$200
Daiichi Sankyo Inc.4$192
AbbVie7$189
Amgen10$171
Bayer3$163
Novocure Inc.5$161
Sanofi6$156
Pharmacosmos Therapeutics Inc.5$132
Exelixis Inc.7$129
Genentech USA, Inc.5$121
Servier Pharmaceuticals LLC5$111
Puma Biotechnology, Inc.1$110
Jazz Pharmaceuticals Inc.5$109
Global Blood Therapeutics, Inc.1$108
Regeneron Healthcare Solutions, Inc.4$104
Karyopharm Therapeutics Inc.4$102
Boehringer Ingelheim4$98
Array Biopharma Inc5$97
Mirati Therapeutics, Inc.4$88
Sanofi-aventis U.S. LLC1$87
ADC Therapeutics America, Inc.5$85
Bristol Myers Squibb4$83
Beigene USA, Inc.4$81
GSK4$81
Taiho Oncology, Inc.4$79
Coherus Oncology, Inc.4$75
Pharmacyclics LLC, An Abbvie Company4$67
Accord Healthcare, Inc.3$64
Lilly USA, LLC3$61
Genmab U.S., Inc.2$54
Morphosys, US Inc.3$52
Deciphera Pharmaceuticals Inc.2$49
Amneal Pharmaceuticals LLC2$47
Seagen Inc.2$45
Acrotech Biopharma Inc.2$45
Beone Medicines USA, Inc.2$43
Adaptive Biotechnologies Corporation2$42
Alnylam Pharmaceuticals Inc.2$41
Tersera Therapeutics LLC2$39
Spectrum Pharmaceuticals Inc.2$39
Gilead2$36
Rigel Pharmaceuticals, Inc.2$31
Fresenius Kabi USA, LLC1$30
Recordati_rare_diseases_inc.1$28
Tempus AI, Inc1$25
Epizyme, Inc.1$22
Agios Pharmaceuticals, Inc.1$22
CTI Biopharma Corp.1$21
Phadia US Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,202 in reported general payments places this provider in the 95th percentile of 158 women's health providers in North Carolina.

See all women's health providers in North Carolina

Medicare billing

Part B allowed, 2024
$27,695
Medicare patients
17
Services billed
690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$41,772
Ondansetron OdtOndansetron38$838
Oxycodone Hcl37$663
Prochlorperazine Maleate22$446
Acyclovir20$348
Dexamethasone12$319
Olanzapine27$242
Pantoprazole Sodium11$192
Tramadol Hcl29$127
Gabapentin14$123
Prednisone18$84
Zolpidem Tartrate14$75
Lorazepam14$16

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$362$41,77272 claims
Lilly USA, LLCOlanzapine$61$24227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 158 women's health providers in North Carolina.

Other women's health in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →